Drug Detail:Lithobid (Lithium [ lith-ee-um ])
Generic Name: LITHIUM CARBONATE 300mg
Dosage Form: tablet, film coated, extended release
Drug Class: Antimanic agents
Drug Detail:Lithobid (Lithium [ lith-ee-um ])
Generic Name: LITHIUM CARBONATE 300mg
Dosage Form: tablet, film coated, extended release
Drug Class: Antimanic agents
Acute Mania
Optimal patient response can usually be established with 1800 mg/day in the following dosages:
1Can also be administered on 600 mg TID recommended dosing interval. | |||
ACUTE MANIA |
|||
Morning |
Afternoon |
Nighttime |
|
LITHOBID® |
3 tabs |
3 tabs |
Such doses will normally produce an effective serum lithium concentration ranging between 1.0 and 1.5 mEq/L. Dosage must be individualized according to serum concentrations and clinical response. Regular monitoring of the patient's clinical state and of serum lithium concentrations is necessary. Serum concentrations should be determined twice per week during the acute phase, and until the serum concentrations and clinical condition of the patient have been stabilized.
Long-Term Control
Desirable serum lithium concentrations are 0.6 to 1.2 mEq/L which can usually be achieved with 900 to 1200 mg/day. Dosage will vary from one individual to another, but generally the following dosages will maintain this concentration:
1Can be administered on TID recommended dosing interval up to 1200 mg/day. | |||||||
LONG-TERM CONTROL |
|||||||
Morning |
Afternoon |
Nighttime |
|||||
LITHOBID® Extended-Release Tablets1 |
2 tabs (600 mg) |
2 tabs (600 mg) |
Serum lithium concentrations in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months. Patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations of 1.0 to 1.5 mEq/L. Geriatric patients often respond to reduced dosage, and may exhibit signs of toxicity at serum concentrations ordinarily tolerated by other patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Important Considerations